CellWell record HH-3797
Minutes of the 74th meeting of the Medicines Classification Committee: lithium reclassification
New Zealand Medicines Classification Committee
Medsafe New Zealand ยท 2025
In plain language
Documents international regulatory review and differing global treatment of low-dose lithium -- Committee found insufficient information on adverse reactions interactions and study quality and did not recommend reclassification; lithium remained prescription except existing dermal exceptions
- Design
- Regulatory document
Cite this record: https://thecellwell.org/studies/HH-3797
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.